surpass cvot tirzepatide results 💡 New insight in diabetes care: In patients with T2DM and ASCVD, the SURPASS-CVOT trial found that was noninferior to dulaglutide for major cardiovascular events (12.2% vs 13.1%; HR 0.92). What Tirzepatide in SURPASS‑CVOT: Favorable Cardiovascular

We don't have the brain energy to follow through on things

Additional findings suggest that DSIP may influence withdrawal responses in cases where subjects are dependent on traditional pain medications, potentially reducing rebound pain symptoms that arise during discontinuation

Reduction in the Incidence of Type 2 Diabetes With Lifestyle Intervention or Metformin

doi: 10.1007/s00125-005-1787-2

Phenotyping pharyngeal pathophysiology using polysomnography in patients with obstructive sleep apnea

The AASLD now recommends identifying MASH candidates using non-invasive tests such as vibration-controlled transient elastography, MR elastography, or enhanced liver fibrosis score rather than liver biopsy, which lowers the barrier to diagnosis and treatment